Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 2
1998 3
1999 4
2000 2
2001 2
2002 2
2003 1
2004 1
2005 3
2006 2
2007 4
2008 2
2009 1
2010 2
2011 4
2012 7
2013 7
2014 5
2015 9
2016 7
2017 7
2018 2
2019 8
2020 8
2021 9
2022 12
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

115 results

Results by year

Filters applied: . Clear all
Page 1
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression.
Vanhersecke L, Brunet M, Guégan JP, Rey C, Bougouin A, Cousin S, Moulec SL, Besse B, Loriot Y, Larroquette M, Soubeyran I, Toulmonde M, Roubaud G, Pernot S, Cabart M, Chomy F, Lefevre C, Bourcier K, Kind M, Giglioli I, Sautès-Fridman C, Velasco V, Courgeon F, Oflazoglu E, Savina A, Marabelle A, Soria JC, Bellera C, Sofeu C, Bessede A, Fridman WH, Loarer FL, Italiano A. Vanhersecke L, et al. Among authors: soubeyran i. Nat Cancer. 2021 Aug;2(8):794-802. doi: 10.1038/s43018-021-00232-6. Epub 2021 Aug 12. Nat Cancer. 2021. PMID: 35118423 Free PMC article.
Standardized Pathology Screening of Mature Tertiary Lymphoid Structures in Cancers.
Vanhersecke L, Bougouin A, Crombé A, Brunet M, Sofeu C, Parrens M, Pierron H, Bonhomme B, Lembege N, Rey C, Velasco V, Soubeyran I, Begueret H, Bessede A, Bellera C, Scoazec JY, Italiano A, Fridman CS, Fridman WH, Le Loarer F. Vanhersecke L, et al. Among authors: soubeyran i. Lab Invest. 2023 May;103(5):100063. doi: 10.1016/j.labinv.2023.100063. Epub 2023 Jan 18. Lab Invest. 2023. PMID: 36801637
Spatial transcriptomics of macrophage infiltration in non-small cell lung cancer reveals determinants of sensitivity and resistance to anti-PD1/PD-L1 antibodies.
Larroquette M, Guegan JP, Besse B, Cousin S, Brunet M, Le Moulec S, Le Loarer F, Rey C, Soria JC, Barlesi F, Bessede A, Scoazec JY, Soubeyran I, Italiano A. Larroquette M, et al. Among authors: soubeyran i. J Immunother Cancer. 2022 May;10(5):e003890. doi: 10.1136/jitc-2021-003890. J Immunother Cancer. 2022. PMID: 35618288 Free PMC article.
Genomics to select treatment for patients with metastatic breast cancer.
Andre F, Filleron T, Kamal M, Mosele F, Arnedos M, Dalenc F, Sablin MP, Campone M, Bonnefoi H, Lefeuvre-Plesse C, Jacot W, Coussy F, Ferrero JM, Emile G, Mouret-Reynier MA, Thery JC, Isambert N, Mege A, Barthelemy P, You B, Hajjaji N, Lacroix L, Rouleau E, Tran-Dien A, Boyault S, Attignon V, Gestraud P, Servant N, Le Tourneau C, Cherif LL, Soubeyran I, Montemurro F, Morel A, Lusque A, Jimenez M, Jacquet A, Gonçalves A, Bachelot T, Bieche I. Andre F, et al. Among authors: soubeyran i. Nature. 2022 Oct;610(7931):343-348. doi: 10.1038/s41586-022-05068-3. Epub 2022 Sep 7. Nature. 2022. PMID: 36071165 Clinical Trial.
[Oesogastric cancer - new therapeutic targets].
Palmieri LJ, Soubeyran I, Pernot S. Palmieri LJ, et al. Among authors: soubeyran i. Bull Cancer. 2023 May;110(5):560-569. doi: 10.1016/j.bulcan.2022.08.005. Epub 2022 Nov 10. Bull Cancer. 2023. PMID: 36371284 Review. French.
Circulating tumor DNA landscape and prognostic impact of acquired resistance to targeted therapies in cancer patients: a national center for precision medicine (PRISM) study.
Bayle A, Belcaid L, Palmieri LJ, Teysonneau D, Cousin S, Spalato-Ceruso M, Aldea M, Vasseur D, Alame M, Blouin L, Soubeyran I, Nicotra C, Ngocamus M, Hollebecque A, Loriot Y, Besse B, Lacroix L, Rouleau E, Barlesi F, Andre F, Italiano A. Bayle A, et al. Among authors: soubeyran i. Mol Cancer. 2023 Nov 4;22(1):176. doi: 10.1186/s12943-023-01878-9. Mol Cancer. 2023. PMID: 37924050 Free PMC article.
Prostate cancer and PARP inhibitors: progress and challenges.
Teyssonneau D, Margot H, Cabart M, Anonnay M, Sargos P, Vuong NS, Soubeyran I, Sevenet N, Roubaud G. Teyssonneau D, et al. Among authors: soubeyran i. J Hematol Oncol. 2021 Mar 29;14(1):51. doi: 10.1186/s13045-021-01061-x. J Hematol Oncol. 2021. PMID: 33781305 Free PMC article. Review.
Multicenter Harmonization Study of Pan-Trk Immunohistochemistry for the Detection of NTRK3 Fusions.
Adam J, Stang NL, Uguen A, Badoual C, Chenard MP, Lantuéjoul S, Maran-Gonzalez A, Robin YM, Rochaix P, Sabourin JC, Soubeyran I, Sturm N, Svrcek M, Vincent-Salomon A, Radosevic-Robin N, Penault-Llorca F. Adam J, et al. Among authors: soubeyran i. Mod Pathol. 2023 Aug;36(8):100192. doi: 10.1016/j.modpat.2023.100192. Epub 2023 Apr 20. Mod Pathol. 2023. PMID: 37084942
Therapeutic strategies in elderly and very elderly patients.
Soubeyran P, Henriques de Figueiredo B, Soubeyran I, Mertens C, Cazeau AL. Soubeyran P, et al. Among authors: soubeyran i. Best Pract Res Clin Haematol. 2012 Mar;25(1):91-100. doi: 10.1016/j.beha.2012.01.009. Epub 2012 Feb 22. Best Pract Res Clin Haematol. 2012. PMID: 22409826 Review.
Pan-TRK immunohistochemistry in gynaecological mesenchymal tumours: diagnostic implications and pitfalls.
Moura MS, Costa J, Velasco V, Kommoss F, Oliva E, Le Loarer F, McCluggage WG, Razack R, Treilleux I, Mills A, Longacre T, Devouassoux-Shisheboran M, Hostein I, Azmani R, Blanchard L, Hartog C, Soubeyran I, Khalifa E, Croce S. Moura MS, et al. Among authors: soubeyran i. Histopathology. 2024 Feb;84(3):451-462. doi: 10.1111/his.15082. Epub 2023 Nov 21. Histopathology. 2024. PMID: 37988282
115 results